NasdaqGS - Nasdaq Real Time Price USD

Alnylam Pharmaceuticals, Inc. (ALNY)

Compare
244.89 -1.91 (-0.77%)
At close: 4:00 PM EST
244.11 -0.78 (-0.32%)
After hours: 4:53 PM EST
Currency in USD All numbers in thousands
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
2,094,795.00
1,828,292.00
1,037,418.00
844,287.00
492,853.00
Cost of Revenue
306,411.00
310,406.00
168,817.00
140,144.00
78,052.00
Gross Profit
1,788,384.00
1,517,886.00
868,601.00
704,143.00
414,801.00
Operating Expense
1,976,514.00
1,800,061.00
1,653,673.00
1,412,795.00
1,243,239.00
Operating Income
-188,130.00
-282,175.00
-785,072.00
-708,652.00
-828,438.00
Net Non Operating Interest Income Expense
-12,846.00
-25,660.00
-131,160.00
-141,442.00
-72,687.00
Other Income Expense
-120,128.00
-125,682.00
-210,761.00
-2,050.00
45,525.00
Pretax Income
-321,104.00
-433,517.00
-1,126,993.00
-852,144.00
-855,600.00
Tax Provision
11,160.00
6,725.00
4,163.00
680.00
2,681.00
Net Income Common Stockholders
-332,264.00
-440,242.00
-1,131,156.00
-852,824.00
-858,281.00
Diluted NI Available to Com Stockholders
-332,264.00
-440,242.00
-1,131,156.00
-852,824.00
-858,281.00
Basic EPS
-2.62
-3.52
-9.30
-7.20
-7.46
Diluted EPS
-2.62
-3.52
-9.30
-7.20
-7.46
Basic Average Shares
126,775.00
124,906.00
121,689.00
118,451.00
114,986.00
Diluted Average Shares
126,775.00
124,906.00
121,689.00
118,451.00
114,986.00
Total Operating Income as Reported
-188,130.00
-282,175.00
-785,072.00
-708,652.00
-828,438.00
Rent Expense Supplemental
155,050.00
145,687.00
131,967.00
97,259.00
--
Total Expenses
2,282,925.00
2,110,467.00
1,822,490.00
1,552,939.00
1,321,291.00
Net Income from Continuing & Discontinued Operation
-332,264.00
-440,242.00
-1,131,156.00
-852,824.00
-858,281.00
Normalized Income
-232,968.90
-354,968.61
-969,555.97
-865,425.26
-885,186.61
Interest Income
121,379.00
95,561.00
24,808.00
1,579.00
11,809.00
Interest Expense
134,225.00
121,221.00
155,968.00
143,021.00
84,496.00
Net Interest Income
-12,846.00
-25,660.00
-131,160.00
-141,442.00
-72,687.00
EBIT
-186,879.00
-312,296.00
-971,025.00
-709,123.00
-771,104.00
EBITDA
-85,690.00
-215,265.00
-885,475.00
-619,429.00
-696,669.00
Reconciled Cost of Revenue
306,411.00
310,406.00
168,817.00
140,144.00
78,052.00
Reconciled Depreciation
101,189.00
97,031.00
85,550.00
89,694.00
74,435.00
Net Income from Continuing Operation Net Minority Interest
-332,264.00
-440,242.00
-1,131,156.00
-852,824.00
-858,281.00
Total Unusual Items Excluding Goodwill
-125,690.00
-107,941.00
-204,557.00
17,262.00
36,857.00
Total Unusual Items
-125,690.00
-107,941.00
-204,557.00
17,262.00
36,857.00
Normalized EBITDA
40,000.00
-107,324.00
-680,918.00
-636,691.00
-733,526.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
-26,394.90
-22,667.61
-42,956.97
4,660.74
9,951.39
12/31/2020 - 6/1/2004

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers